Nuklearmedizin 2002; 41(05): 224-229
DOI: 10.1055/s-0038-1625292
Editorial
Schattauer GmbH

A new technique of 99mTc-ciprofloxacin kit preparation

Neue Methode der Zubereitung des 99mTc-Ciprofloxacin-Kits
I. Kleisner
1   Department of Nuclear Medicine, Kralovske Vinohrady University Hospital
,
P. Komarek
2   Pharmaceutical Technology and Drug Control, Postgraduate Medical School
,
I. Komarkova
3   Radiopharmacy, State Institute for Drug Control
,
M. Konopkova
4   Nuclear Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
› Author Affiliations
Further Information

Publication History

Received: 22 April 2002

17 June 2002

Publication Date:
11 January 2018 (online)

Summary

Aim: Development of a simple and reproducible method for preparing a ciprofloxacin kit using a redox polymer, which would meet the requirements for an easy and reliable technique of labelling with 99mTc and diagnostic efficiency in scintigraphic imaging of infections. Material and methods: To prepare the kit, an insoluble redox polymer containing an end α(β)-alanine-N, N’-diacetate group anchored to the dextran matrix was used. The redox polymer synthesised by the authors was incubated at room temperature (10 h) with a solution of ciprofloxacin (1%) in a suspension (5%). The mixture was then filtered and dispensed into sterile vials (0.2 ml each). The kit was labelled with 99mTc for 10 min at room temperature. The radiochemical purity of the ciprofloxacin-99mTc complex was determined by ITLC and paper chromatography in relation to the following factors: pH, total content of ciprofloxacin, volume of sodium 99mTc-pertechnetate. Ciprofloxacin biodistribution was evaluated in Wistar rats with Staphylococcus aureus infection in the left inguinal region 24 h after abscess induction. Accumulation of 99mTc activity was determined both using external gamma camera imaging and counting dissected tissues 1 h after administration. Results: Radiochemical purity is >95% for kit-labelling (pH 3.3-3.7). With pH 3.45, labelled ciprofloxacin shows the highest stability and radiochemical purity. The 99mTc-ciprofloxacin complex is stable for at least 8 h. In experimentally induced inflammation, the amount of accumulated 99mTc-ciprofloxacin activity is five times higher than in controls. Conclusion: The developed method of 99mTc-ciprofloxacin kit preparation employs a redox polymer in a new procedure, which enables the preparation of a stable kit with a high 99mTc-labelling efficiency. The labelled kit is suitable for scintigraphic imaging of infection.

Zusammenfassung

Ziel: Entwicklung einer einfachen und reproduzierbaren Methode basierend auf einem Redoxpolymer zur verlässlichen Markierung und präzisen Szintigraphie von Infektionsherden. Methoden: Zur Herstellung des Kits wurde ein unlösliches Redoxpolymer mit endständiger α(β)-Alanin-N, N’-diazetatgruppe, gebunden an eine Dextranmatrix, benutzt. Das von den Autoren synthetisierte Redoxpolymer wurde in 5%iger Suspension 10 h bei Zimmertemperatur mit einer Ciprofloxacinlösung (1%) inkubiert. Danach wurde die filtrierte Mixtur in sterile Reagenzgläser gefüllt (je 0,2 ml). Die Markierung des Kits mit 99mTc erfolgte bei Zimmertemperatur (Dauer: 10 min). Die radio-chemische Reinheit von 99mTc-Ciprofloxacin wurde durch ITLC und Papierchromatographie getestet. Berücksichtigt wurden folgende Faktoren: pH, Ciprofloxacin-Gesamtgehalt, Natrium-99mTc-pertechnetat-Volumen. Die Ciprofloxacin-Biodistribution wurde bei Wistar-Ratten mit abszessförmiger Staphylococcus-aureus-Infektion der linken Inguinalregion nach 24 h untersucht. Die Anreicherung der 99mTc-Aktivität wurde mittels Gamma-kameraszintigraphie beurteilt. Ergebnisse: Radio-chemische Reinheit der Kit-Markierung >95% (pH 3,3-3,7). Bei pH 3,45 besitzt das markierte Ciprofloxacin die höchste Stabilität und radiochemische Reinheit. Der 99mTc-Ciprofloxacin-Komplex bleibt mindestens 8 h stabil. Die Anreicherung von 99mTcCiprofloxacin in Gewebe mit experimentell induzierter Entzündung ist fünfmal höher als im Kontrollgewebe. Schlussfolgerung: Die vorgestellte Methode der 99mTcCiprofloxacin-Kit-Herstellung basierend auf einem neuartigen Redoxpolymer führt zu stabilen Kits mit hoher Markierung, die zur szintigraphischen Darstellung von Infektionen geeignet sind.

 
  • References

  • 1 Britton KE, Vinjamuri S, Hall AV. et al. Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection. Eur J Nucl Med 1997; 24: 553-6.
  • 2 Britton KE, Wareham DW, Das SS. Concerns about 99mTc-labelled ciprofloxacin for infection detection. Eur J Nucl Med 2001; 28: 779-81.
  • 3 Buscombe JR, Miller RF, Lui D. et al. Combined Gallium-67-citrate and 99mTc-human immunoglobulin imaging in human immuno-deficiency virus-positive patients with fever of unknown origin. Nucl Med Commun 1991; 12: 583-92.
  • 4 Ciprinol inj. – Summary of product characteristics, Krka, Slovenia (2000).
  • 5 De Winter F, van de Wiele Ch, Dumont F. et al. Biodistribution and dosimetry of 99mTc-ciprofloxacin, a promising agent for the diagnosis of bacterial infection. Eur J Nucl Med 2001; 28: 570-4.
  • 6 Kleisner I, Komarek P, Komarkova I. et al. The use of redox polymers in labelling procedures of proteins and peptides with 99mTc. I. Properties of redox polymers and technique of labelling. Nucl Med Rev 2000; 3: 65-8.
  • 7 Komarek P, Kleisner I, Komarkova I. et al. The use of redox polymers in labelling procedures of proteins and peptides with 99mTc. II. Technique of preparations of kits for protein labelling by 99mTc and its effect on stability and radio-chemical purity. Nucl Med Rev 2000; 3: 69-72.
  • 8 McAfee JG, Gagne G, Subramanian G. et al. The localisation of indium-111-leukocytes, gallium-67, polyclonal IgG and other radioactive agents in acute focal inflammatory lesions. J Nucl Med 1991; 32: 2126-31.
  • 9 Martins PA, Faintuch BL, Pereira NPS. et al. Optimization of labeling ciprofloxacin with 99mTc and biodistribution in normal and infected rats. J Nucl Med 2001; 42: 264P.
  • 10 Pirmettis I, Limouris GS, Papadopoulos M. et al. Potential infection imaging agents: preparation and biodistribution of 99mTc-norfloxacin and 99mTc-ciprofloxacin. Eur J Nucl Med 1999; 26: 1108.
  • 11 Seabold JE, Forstrom LA, Schauwecker DS. et al. Procedure guideline for indium-111-leukocyte scintigraphy for suspected infection/ inflammation. J Nucl Med 1997; 38: 997-1001.
  • 12 Seabold JE, Palestro CJ, Brown ML. et al. Procedure guideline for gallium scintigraphy in inflammation. J Nucl Med 1997; 38: 994-7.
  • 13 Schrijver MD, Streule K, Senekowitsch R. et al. Scintigraphy of inflammation with nanometer-sized colloidal tracers. Nucl Med Commun 1987; 8: 895-908.
  • 14 Spinelli F, Milella M, Sara R. et al. The value of 99mTc-labelled human immunoglobulin scanning in the evaluation of Crohn´s disease. Eur J Nucl Med 1990; 16: 436.
  • 15 Staab EV, McCartney H. Role of 67Gallium in inflammatory disease. Semin Nucl Med 1978; 8: 219-34.
  • 16 Van der Laken CJ, Boerman OC, Oyen JG. et al. Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction. Eur J Nucl Med 1998; 25: 535-46.
  • 17 Vinjamuri S, Hall AV. Comparison of 99mTc Infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet 1996; 347: 233.